The Linux of Vaccines: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
*Notes: | *Notes: | ||
*''Because vaccines can only be produced in laboratories owned or authorized by the patent holders, most of the world’s pharmaceutical factories lie idle.'' | *''Because vaccines can only be produced in laboratories owned or authorized by the patent holders, most of the world’s pharmaceutical factories lie idle.'' | ||
*''The need to discover the next breakthrough proprietary product has many corrosive effects on research. It incentivizes companies to conceal their findings from each other and from the wider scientific community, even at the cost of human health. The intellectual property–free “open-source” model aims to reverse this and turn research into a multilateral collaborative effort rather than a race to invent and reinvent the wheel. When it comes to COVID-19 specifically, the stalling impact of the contemporary funding model is felt most acutely at the final stages: getting the finished product approved and into use. Whatever time was lost during the early days of the pandemic due to lack of collaboration and trade secrets, virologist Saksela points out, is relatively insignificant. In fact, the development of all first-generation COVID-19 shots has been straightforward.'' | |||
* | |||
Revision as of 18:33, 9 March 2021
- Good article - [1]
- Notes:
- Because vaccines can only be produced in laboratories owned or authorized by the patent holders, most of the world’s pharmaceutical factories lie idle.
- The need to discover the next breakthrough proprietary product has many corrosive effects on research. It incentivizes companies to conceal their findings from each other and from the wider scientific community, even at the cost of human health. The intellectual property–free “open-source” model aims to reverse this and turn research into a multilateral collaborative effort rather than a race to invent and reinvent the wheel. When it comes to COVID-19 specifically, the stalling impact of the contemporary funding model is felt most acutely at the final stages: getting the finished product approved and into use. Whatever time was lost during the early days of the pandemic due to lack of collaboration and trade secrets, virologist Saksela points out, is relatively insignificant. In fact, the development of all first-generation COVID-19 shots has been straightforward.